Purchase this article with an account.
M. Cho, A. J. Kanellopoulos; Safety and Efficacy of Prophylactic Ultraviolet-A-Induced Crosslinking After High-Risk Myopic Photorefractive Keratectomy. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5470.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the safety and efficacy of adjunctive treatment with ultraviolet-A (UVA)-induced crosslinking (CCL) on high-risk myopic patients after photorefractive keratectomy (PRK).
45 high-risk myopic patients underwent PRK using Wavelight excimer laser platform. Pre-operative evaluation included uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), refractive error, keratometry (K), corneal topography (T), pachymetry (P), and endothelial cell count (ECC). Following PRK, the eyes underwent UVA-induced CCL (370 nm, 7 mW/cm2 for 10 minutes) after the administration of 0.1% riboflavin drops. The mean follow-up was 1.6 years (range 1-4 years).
mean UCVA improved from 20/100 (Snellen chart) to 20/15, BSCVA from 20/20 to 20/15, and the spherical equivalent from -6.25D to +0.2D. Mean K changed from 45.5D to 39D, P from 495 to 385, and ECC from 2750 to 2800. None of the cases developed signs of ectasia.
UVA CCL appears to be safe and effective adjunctive treatment to prevent ectasia in high-risk myopic patients undergoing PRK.
This PDF is available to Subscribers Only